HC Wainwright Comments on G1 Therapeutics, Inc.’s Q2 2024 Earnings (NASDAQ:GTHX)

G1 Therapeutics, Inc. (NASDAQ:GTHX) – Stock analysts at HC Wainwright raised their Q2 2024 earnings per share (EPS) estimates for G1 Therapeutics in a report issued on Thursday, May 2nd. HC Wainwright analyst E. White now anticipates that the company will post earnings of ($0.18) per share for the quarter, up from their prior forecast of ($0.19). HC Wainwright currently has a “Buy” rating and a $9.00 price objective on the stock. The consensus estimate for G1 Therapeutics’ current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for G1 Therapeutics’ Q3 2024 earnings at ($0.17) EPS, Q4 2024 earnings at ($0.05) EPS, FY2024 earnings at ($0.61) EPS and FY2025 earnings at ($0.20) EPS.

A number of other equities analysts have also commented on GTHX. Wedbush reiterated an “outperform” rating and issued a $5.00 price objective (up from $4.00) on shares of G1 Therapeutics in a research note on Wednesday, February 28th. Needham & Company LLC reiterated a “buy” rating and issued a $12.00 price objective on shares of G1 Therapeutics in a research note on Wednesday, May 1st.

G1 Therapeutics Trading Down 4.9 %

G1 Therapeutics stock opened at $4.27 on Monday. The company has a debt-to-equity ratio of 1.34, a quick ratio of 2.55 and a current ratio of 2.94. The business’s 50-day simple moving average is $3.98 and its 200-day simple moving average is $3.13. The firm has a market capitalization of $223.24 million, a PE ratio of -6.89 and a beta of 1.71. G1 Therapeutics has a 52 week low of $1.08 and a 52 week high of $5.00.

G1 Therapeutics (NASDAQ:GTHX) last posted its quarterly earnings data on Wednesday, May 1st. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01). The business had revenue of $14.48 million during the quarter, compared to the consensus estimate of $15.21 million. G1 Therapeutics had a negative return on equity of 74.75% and a negative net margin of 36.40%. During the same quarter in the previous year, the firm posted ($0.53) earnings per share.

Institutional Investors Weigh In On G1 Therapeutics

A number of institutional investors have recently added to or reduced their stakes in GTHX. Financial Advocates Investment Management acquired a new stake in G1 Therapeutics during the fourth quarter valued at approximately $39,000. Capstone Investment Advisors LLC acquired a new stake in G1 Therapeutics during the fourth quarter valued at approximately $76,000. Algert Global LLC acquired a new position in shares of G1 Therapeutics in the 3rd quarter worth approximately $98,000. Curi Wealth Management LLC boosted its holdings in shares of G1 Therapeutics by 17.8% in the 3rd quarter. Curi Wealth Management LLC now owns 70,742 shares of the company’s stock worth $102,000 after acquiring an additional 10,700 shares in the last quarter. Finally, Jump Financial LLC acquired a new position in shares of G1 Therapeutics in the 4th quarter worth approximately $105,000. 24.21% of the stock is owned by institutional investors and hedge funds.

Insider Activity at G1 Therapeutics

In related news, insider Rajesh Malik sold 28,600 shares of the business’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $4.62, for a total transaction of $132,132.00. Following the transaction, the insider now directly owns 169,938 shares in the company, valued at $785,113.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 8.23% of the company’s stock.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.